To Customers and Members of the Global Research Community:
Illumina, Inc. recently filed a patent infringement lawsuit against Element Biosciences in the United States. Element has strong respect for the intellectual property system and has built a significant patent portfolio of its own. However, we believe Illumina’s claims are unfounded and represent an anticompetitive effort to limit choice and stifle innovation in genomic sequencing. The technology described in the asserted patents well predates Illumina, which fundamentally undermines Illumina's hollow public claim that Element lacks a history of innovation. We are confident that Illumina’s claims are meritless.
Element was founded to expand access to high‑quality, affordable sequencing and multiomic analysis. We remain committed to delivering novel solutions—like our AVITI™ and AVITI24™ platforms and the groundbreaking avidite base chemistry (ABC)—that empower researchers and accelerate scientific and medical discovery. We will vigorously defend our technology, our customers, and the broader community’s ability to use the research tools of their choosing without monopolistic constraints. We will not be bullied into submission.
Our mission and dedication to you remains unchanged: we will continue to provide leading‑edge products, transparent pricing, and outstanding support. We do not expect this litigation to affect our ability to supply or service our instruments and consumables.
If you have any questions, please reach out to your Element contact.